Barinthus Biotherapeutics plc (NASDAQ:BRNS) Sees Large Decline in Short Interest

Barinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) was the recipient of a large decrease in short interest during the month of August. As of August 15th, there was short interest totalling 9,700 shares, a decrease of 34.5% from the July 31st total of 14,800 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 23,800 shares, the days-to-cover ratio is presently 0.4 days.

Barinthus Biotherapeutics Stock Up 0.4 %

BRNS stock traded up $0.01 during midday trading on Thursday, hitting $1.28. The company's stock had a trading volume of 25,494 shares, compared to its average volume of 20,658. Barinthus Biotherapeutics has a 12 month low of $1.18 and a 12 month high of $5.10. The firm has a market capitalization of $50.46 million, a price-to-earnings ratio of -0.70 and a beta of -0.52. The company has a 50 day moving average of $1.39 and a two-hundred day moving average of $2.07.

Barinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.01). On average, analysts anticipate that Barinthus Biotherapeutics will post -1.91 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Alphabet Inc. bought a new position in shares of Barinthus Biotherapeutics during the 2nd quarter valued at approximately $2,119,000. Catalina Capital Group LLC bought a new position in shares of Barinthus Biotherapeutics during the 2nd quarter valued at approximately $25,000. Ipswich Investment Management Co. Inc. bought a new position in shares of Barinthus Biotherapeutics during the 2nd quarter valued at approximately $32,000. M&G Plc bought a new position in shares of Barinthus Biotherapeutics during the 2nd quarter valued at approximately $7,276,000. Finally, BlueCrest Capital Management Ltd bought a new position in shares of Barinthus Biotherapeutics during the 1st quarter valued at approximately $1,292,000. 25.20% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

BRNS has been the subject of several analyst reports. Barclays reduced their target price on shares of Barinthus Biotherapeutics from $7.00 to $3.00 and set an "overweight" rating for the company in a report on Thursday, June 13th. HC Wainwright reissued a "buy" rating and issued a $5.00 target price on shares of Barinthus Biotherapeutics in a report on Monday, August 12th. Alliance Global Partners reduced their target price on shares of Barinthus Biotherapeutics from $11.00 to $9.50 and set a "buy" rating for the company in a report on Tuesday, August 13th. Finally, William Blair reissued an "outperform" rating on shares of Barinthus Biotherapeutics in a report on Thursday, June 13th.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.